Section 1260H decoded: How Chinese biotech builds trust in the U.S.

Section 1260H & WuXi AppTec

• 1260H is a policy signaling tool, not a sanction – identifies companies linked to China's military-civil fusion
• Creates indirect but real consequences: investor scrutiny, partner caution, ESG risk perception
• WuXi AppTec (listed) vs. WuXi Biologics (not): difference = value chain position. AppTec sits upstream (discovery, data, genomics) → more sensitive. Biologics is downstream (manufacturing) → less scrutinized

Policy Landscape

• 1260H = identification layer; Biosecure Act = enforcement layer (funding restrictions, procurement limits)
• Broader ecosystem: CFIUS, export controls, NIH rules, federal procurement – all filter biotech participation

Strategic Responses

• Lobbying: engage distributed stakeholders (think tanks, industry associations, academic networks) – not just regulators
• Narrative: reposition from "China service provider" to "global innovation infrastructure player"
• Identity: don't hide origin – contextualize it. Build trust through governance transparency, partnerships, ecosystem embedding

MedAsian's Role

• Policy intelligence (early warning)
• Narrative building (strategic framing)
• Stakeholder ecosystem construction
• Crisis preparedness & scenario planning

Conclusion: Internationalization ≠ acceptance. Goal is global competitiveness under governance constraints – trust is built through sustained participation, not messaging.

Transcript

SPEAKER_00 0:04

Welcome back to your podcast with MedAsian. I'm Rex, and this is the show where we look past the surface level questions, past just how do you get into your market and dig into what it actually takes for healthcare companies, especially Chinese biotech and life science firms, to build long-term durable success in places like the US and Europe. And today we're tackling one of the most talked about, most misunderstood stories in global biotech right now. The inclusion of USI apptech in the US Department of Defense is Section 1268 list. Now, if you follow biotech news, you've seen the hairlines. But what does this actually mean? Is it a sanction? Is it a ban? Is it just a political signal? Or is it something more structural that will re reshape how the entire CDMO and CRO sector is viewed? And behind the specific case, there is a bigger question that a lot of executives and funders are quietly asking. If this can happen to a company as globally integrated as WC ApTech, what does it mean for my company? What do I need to understand about how policy, perception, and the geopolitics interact in the US? And how do I navigate that? To help us decode all of this, I'm joined by Felix, who leads government affairs and strategic policy work across a number of the most sensitive cross-border healthcare and life science engagements today. Felix, thanks for being here. Great to be with you, Rex. All right, let's straight in. I think the natural place to start is the headline that a lot of people read and not quite know what to do with. Felix, in practical terms, what is the significance of UC FTEC being listed under section 1268, and why does it matter?

SPEAKER_01 2:21

The inclusion of UC ApTech in the US section 1260H list is important, but not because it functions like a sanction or an immediate restriction. It's better understood as a policy-level signal, a way for the US government to formally flag companies that may be considered strategically sensitive within the border of US-China technology and the national security context. Section 1260H itself is part of the National Defense Authorization Act, and its main function is to identify companies that are perceived to have connections to China's military civil fusion ecosystem. So, in practical terms, it's less about enforcement and more about signaling and categorization. But in Washington and in capital markets, signaling itself can have very real consequences. What makes this meaningful is that once a company is placed into that category, it begins to be viewed through a different lens by a wide range of stakeholders, not just policymakers, but also investors, multinational farming partners, and even ESG and compliance teams inside global corporations. In WC AppTax case, the concern is largely tied to a broader themes that are increasingly central in U.S. policy discussions around biotechnology, such as the dual usage capabilities, data sensitivity, and the strategic importance of life science infrastructure as a deeply integrated global CRO platform that sits at the center of pharma RD workflows. UC EpTech is involved in early stage discovery, complex data-driven research process, and large-scale corporate collaboration with global pharma companies. It's this approximate to high-level biomedical data and innovation infrastructure that likely contributes to how it is being interpreted within this policy framework. The impact of this kind of listing is not necessarily immediate or operational in a direct sense, but it is cumulative and multidimensional. On the capital market side, it can influence how index providers, institutional investors, and ESG frameworks assess exposure, which in turn can create passive pressure on valuation and funding perception. On the commercial side, it can lead to a more cautious engagement from the US and multinational partners, especially in areas involving sensitive data, early-stage research and development collaboration or government-linked funding. And on the policy side, it contributes to a broader narrative shift where biotech companies are increasingly evaluated not only as commercial entities, but also as potential strategic infrastructure, not within a national security context. Over time, this doesn't just affect one company. It can reshape how an entire category of life science infrastructure providers is being perceived globally.

SPEAKER_00 6:09

So it's less about an immediate operational ban and more about a policy signal that reshapes how investors and partners perceive risk, which makes me wonder what exactly is Section 126H and how does it tie into the Biosecure Act?

SPEAKER_01 6:32

Section 1260H of the US National Defense Authority Act, or NDAA, is essentially a policy tool that requires the Department of Defense to identify companies that are believed to be linked to China's military civil fusion ecosystem. The important thing to understand is that this is not a sanctioned list and it doesn't directly restrict a company's operations. Instead, it functions more as a risk identification and signaling framework. In other words, it creates visibility both inside government and across the broader policy and investment ecosystem around companies that may be considered strategically sensitive, particularly in emerging technology areas like biotech, AI, semiconductors, and advanced materials. What makes 1260H meaningful in practice is that once a company appears on that list, it enters a different category of perception. Even without immediate legal consequences, it can influence how policymakers think about the sector, how institutional investors evaluate exposure, and how corporate compliance teams approach partnerships. So the effect is often indirect, but still very real over time, because it it shapes the baseline assumptions that different stakeholders use when assessing risk. Now, when you compare that to the Biosecure Act, the difference is largely about where it sits in the policy stack. If 1260H is about identification and the labeling, the Biosecure Act is closer to implementation or enforcement layer. It reflects a more operational policy direction where identified concerns can translate into actual behavioral constraints. Things like restrictions on federal funding, limitations on procurement, it's entire rules around collaboration with designated entities. So you can think of it as 1268 saying this is something we're watching closely while the biosecure framework moves toward, and here are the rules that may apply as a result. And then zooming out further, both of these mechanisms sit within a much broader ecosystem of the US regulatory and national security pools. That can affect Chinese lifelines and biotech companies. For example, CFAS reviews can impact inbound investment and acquisitions. Export control regimes and entity lists can restrict access to certain technologies or equipment. NIH and NSF founding rules can limit research collaboration opportunities, and federal procurement policies can effectively exclude companies from certain government-related contracts. When you look at all of this together, what emerges is not a single policy, but a layer and increasingly structured framework that filters biotech participation through the lens of strategic sensitivity. So the overall direction is quite clear. It's not just about regulating individual companies, but about building a system that evaluates how deeply integrated certain firms are within critical technology ecosystems, especially where healthcare data and national security start to overlap.

SPEAKER_00 10:42

But it raises the next puzzle. Why was UC Biologics treated differently?

SPEAKER_01 10:51

That's a great point, Rex. So the difference treatment between USI ApTech and UC Biologics really highlights an important nuance in how U.S. policy frameworks tend to look at the biotech industry. It's not just about whether companies sit under the name Life Science Umbrella, but more about where exactly they sit in the overall value chain and how close they are to data, early innovation, and potentially sensitive technologies. In the case of UCFTech, the company is much more deeply embedded in early stage drug discovery and preclinical research workflows. That means it often sits at the front end of the innovation pipeline, where a lot of the most sensitive inputs exist. Things like genomic data, early compound screening, AI-driven discovery platforms, and cross-border research and development collaboration. From an American policy perspective, that approximate to high-level to high-value biomedical data and upstream innovation ecosystems tend to raise more questions, particularly in discussions around the dual usage of technology, data security, and the strategic competition in emerging tech sectors. By contrast, we see biologics is primarily focused on downstream biologics development and large-scale manufacturing. In simpler terms, it is more involved in taking already defined biological candidates and scaling them into commercial production. While this is still a critical part of the global pharmaceutical supply chain, it is generally viewed as less sensitive from a national security standpoint because it involves less exposure to early stage discovery data and fewer touch points with perpetuary research inputs. The work is highly technical and strategically important from a supply chain perspective, but it is not usually seen as sitting at the same level of data-driven innovation sensitivity. What this really shows is that in the current US policy framework, classification decisions are not purely based on industry labels like biotech or pharma services. Instead, there's a much more granular way of thinking about where the companies sit in the innovation stack. Companies that are closer to discovery, data generation, and the platform level research and the development integration are more likely to be viewed through a national security lenses, while those further downstream in manufacturing and production are often treated with comparatively less scrutiny. Over time, this kind of logic is becoming increasingly important because it effectively means that where you operate in the value chain can matter just as much as what industry you are in.

SPEAKER_00 14:08

So the differentiating factor is really proximity to early stage data and discovery, which means the strategic question becomes given that classification, what can Uchi ApTech actually do about it in Washington?

SPEAKER_01 14:26

For a company like UCI ApTech, response responding to something like 1260H listing really goes far beyond legal or compliance work. In a US context, this is not just a legal classification issue. It becomes a government affairs and a narrative problem at the same time. What that means in practice is that you're not only dealing with regulators or defense-related agencies, but also with a much wider ecosystem that actually shapes how policy decisions are interpreted and reinforced over time. In Washington, influence doesn't sit in one place. It's distributed across congressional staffers, think tanks, industry associations, academic researchers, and even patient advocacy groups. These stakeholders often don't write the final regulations, but they absolutely shape the environment in which those regulations are formed. They influence how risks are framed, how companies are perceived, and how policy intent is translated into real-world decision making. So for a company in Wucci Atex position, engagement has to happen across all of these layers, not just at the formal regulatory level, but also in the broader opinion-shaping ecosystem that surrounds it. Meanwhile, there's a second layer to the challenge, which is narrative positioning. Once a company is placed into a sensitive policy category, the key question becomes how it is fundamentally understood in the market. If the dominant perception is that it is simply a China-based service provider, then every interaction, whether commercial, regulatory, or financial, will be filtered through that lens. So the strategic objective becomes shifting that perception towards something more structural and global. Positioning the company as a critical infrastructure player in global pharmaceutical innovation rather than as a geographically defined outsourcing provider. In practical terms, that kind of repositioning is not achieved through messaging alone. It usually requires deeper operational proof points that can include stronger and more visible integration with U.S. and multinational pharmaceutical clients, clearer government structures around data security and compliance, and active participation in industry coalitions that reinforce the company's role within the U.S. healthcare and innovation ecosystem. Over time, these actions help shift the conversation from where the company is from to what the company action enables. Ultimately, in Washington and in the broader American policy environments, legitimacy is rarely built through compliance alone. Compliance is the baseline. It gets you in the room. But what sustains long-term credibility is something more structural, consistent engagement, network presence across multiple stakeholder groups, and a narrative that feels aligned with how the US healthcare and innovation system defines trusted participants.

SPEAKER_00 17:50

So it's about repositioning as critical infrastructure through network engagement, not just compliance, which prompts a bigger clock, bigger picture question. What does this listing tell us about in the broader biotech industry beyond just one company?

SPEAKER_01 18:11

The inclusion of UC Apptech in the 1260H framework signals a broader structural shift in how biotech is being perceived globally. Biotech is no longer treated purely as a healthcare or commercial sector. It is increasingly viewed as adjacent to national security due to its convergence with data infrastructure, artificial intelligence, and geonomic technologies. This means that companies operating in this space are increasingly evaluated not just on commercial performance, but also on perceived strategic implications. It also reflects a gradual fragmentation of global trust networks. Even highly integrated global supply chains are now being re-evaluated through geopolitical lenses, and country of origin is becoming one of several variables influencing policy and commercial decisions. This doesn't mean exclusion is automatic, but it does mean uncertainty is structurally higher for companies operating across jurisdictions.

SPEAKER_00 19:33

Shouldn't they try to hide in their Chinese identity when going global?

SPEAKER_01 19:39

A useful way to look at this question is to start by challenging the premise itself. Because in today's global biotech and healthcare environments, hiding identity is not really a workable strategy in the first place. Between regulatory filings, clinical trial disclosures, supply chain transparency requirements, and the capable and capital markets reporting standards, a company's origin is almost always visible. So the real strategic question is not whether to hide an identity, but how to structure and position that identity so it is interpreted in the most constructive way across different markets. From a US and a European perspective, especially, companies are rarely judged on a single dimension like nationality alone. Instead, they're evaluated through multiple overlapping analysis. What they do, how they operate, who they partner with, and how they govern the data, and how they fit into local innovation ecosystems. That means Ingenie is not a fixed label. It's something that gets assembled in the minds of different stakeholders based on repeated interactions and signals over time. So for Chinese life science companies, the more strategic approach is not concealment, but contextualization. In China, they're naturally seen as domestic innovation leaders. In the US, they can simultaneously be positioned as commercial partners embedded in the local pharma ecosystem. And globally, they can be understood as infrastructure contributors to the broader healthcare innovation chain. These identities are not contradictory. They're layered, and the different audiences will emphasize different layers depending on the context. What really matters over time is whether the company can consistently generate trust across signal across all these contexts. That includes governance, transparency, regulatory compliance, maturity, quality of scientific output, and the depth of integration with global partners. In that sense, identity becomes less about what. You are called, and the more about what role you reliably play in the global system. So rather than thinking in terms of hiding or revealing an identity, a more accurate framework is that successful global companies actively manage how their identity is interpreted across different institutional environments, ensuring that origin is just one dimension of perception, not the defining of one.

SPEAKER_00 22:26

So concealment isn't a viable strategy. It's about contextualizing and embedding yourself across multiple layers, which leads to the core challenge. Can a Chinese origin company actively influence how it's perceived within the US system?

SPEAKER_01 22:46

While it's true that a company cannot change its legal origin or the structural facts of where it is incorporated, it can absolutely influence how it is interpreted within the U.S. policy and commercial ecosystem. In practice, perception in the US is not formed through a single decision or a single regulator. It spills gradually through a wide network of institutional relationships, repeated interactions, and accumulated signals over time. In that sense, perception is less about static identity labels and more about institutional embedding. How deeply and naturally a company becomes part of the broader innovation and healthcare system. In the American context, companies are rarely evaluated in isolation. Instead, they're implicitly mapped into ecosystem. A biotech company is not just a foreign entity entering the U.S. market. It is assessed based on whether it behaves like a long-term stakeholder in the system. This includes whether it collaborates with leading hospitals, contributes to academic research, participates in clinical networks, complies transparently with regulatory expectations, and builds durable partnerships with established pharmaceutical players. The more embedded a company becomes in these structures, the more it shifts when being perceived as an external entrance to being seen as a functional participant in the ecosystem. This is where the concept of trust formulation through networks becomes critical. In the US system, trust is not centralized. It is distributed across multiple actors. Regulators like the FDA matter, but so do university researchers who co-publish with the company. And technicians who use or validate its technologies, patient advocacy groups who interpreted its impact, and industry associations that frame its role within the broader sector. Even think tanks and formal policymakers can significantly influence on a company, is discussed in policy circles. Over time, these overlapping relationships formulate a kind of trust perimeter around a company, which can be just as important as formal regulatory status. Another important factor is the consistency of engagement. Perception is not shaped by one-off interactions or communications campaigns. It is shaped by sustained behavior over years. Companies that showed up consistently in collaborative research, industry forms, regulatory consultations, and ecosystem initiatives tend to accumulate what you might call institutional familiarity. That familiarity gradually reduces ambiguity. And in policy environments, reduced ambiguity often translates into reduced perceived risk. At a more strategic level, citizens also influence perception through how they position their role in the innovation system. If they are perceived primarily as transactional service providers, their role will be viewed through a cost or outsourcing lens. But if they are embedded as innovation enablers, supporting drug discovery, accelerating clinical development, or improving global healthcare access, the framing shifts significantly. This shift does not happen through messaging alone. It is reinforced through actual operational integration and the type of partnerships a company can build. So overall, in the US system, perception is not something that can be managed through communication in a narrow sense. It is something that's earned through participation. Companies influence how they are perceived, not by changing who they are, but by continuously expanding where and how they operate within the institutional fabric of the healthcare and life science ecosystem. Over time, the most successful companies are those that are no longer viewed as external participants trying to enter the system, but as embedded actors that the system itself has come to rely on.

SPEAKER_00 27:20

Embedding network trust and consistency over time on the levers. So given all that, how does MetAsian's global GE network actually help companies optionalize this complex positioning? That's a great question.

SPEAKER_01 27:39

So from MetAsian's perspective, the internet nationalization of healthcare companies today is no longer just about entering the US or European markets. That phrase, market access, licensing, distribution has largely become the baseline. What matters now is something more complex and more structural. How companies can view long-term competitiveness in environments where regulation, geopolitics, capital markets, and the public perception are all interacting at the same time. In that sense, government affairs is no longer a downstream support function. It has increasingly become a core layer of global strategy. Through its International Government Affairs Network, which we prefer, which we refer to as the Project Starlink. MedAsian is essentially trying to help companies operate inside this complexity rather than react to it after the fact. The first capability area is policy intelligence. In practical terms, this means building an early warning system that tracks regulatory and legislative developments across the US, Europe, and key Asian markets. Where that's activity in Congress evolving FDA, guidance, NIH funding priorities, or broader national security-related policy shifts. The goal here is not just information gathering, but helping companies anticipate where friction points may emerge before they turn into actual business constraints. The second layer is narrative beauty, which is often underestimated but increasingly decisive in the American context. Markets don't just respond to data, they respond to framing. Two companies with similar technologies can be interpreted very differently depending on how their role is understood. So the objective here is to help reposition companies away from being seen simply as cross-border service providers or China-origin exports and toward being recognizing as global healthcare innovation participants that are contributing to solving shared medical challenges. This is less about messaging in a communication sense and more about building a coherent strategic story that aligns with how U.S. stakeholders, regulators, investors, and partners actually interpret value and risk. The third component is stakeholder ecosystem construction. In the U.S. influence is not centralized. It is distributed across a wide network that includes not only regulators like the FDA, but also academic institutions, hospital systems, industry associations, think techs, patient advocacy groups, and formal policymakers who continue to shape opinion from outside government. What MATASIN is focused on is helping companies build durable relationships across the entire ecosystem so that they're not relying on a narrow set of regulatory channels, but instead are embedded in a broader network of trust and a credibility that spans multiple layers of the healthcare system. The fourth area is risk mitigation and crisis preparedness. In today's environment, risk is no longer hypothetical or episodic. It is structural and continuous. A policy announcement, a congressional hearing, a media narrative shift, or a data governance concern can all have immediate downstream effects on valuation, partnerships, or strategic direction. So the idea here is to help companies move from reactive crisis management to more proactive scenario planning, where they are already prepared for potential regulatory or reputational disruptions before they occur. Ultimately, the way we think about this is quite simple. Internationalization is not the end goal. Being present in global markets is not the same as being accepted in them. The real objective is global competitiveness under governance constraints. And in that context, government affairs is not just about maintaining access. It is about building the underlying infrastructure of trust, predictability, and strategic positioning that allows companies to operate sustainably in complex international systems over the long term.

SPEAKER_00 32:22

Phoenix, this has been incredibly clarifying, and I want to put a few thoughts together because we've covered a lot of ground from the specifics of one listing to the whole architecture of how Chinese life science companies are perceived and how they can operate inside the EO system. If I step back and listen to what you've laid out, a few things really stand out. First, the USI Aptech 126KH listing is not a simple sanction. It's a signal. But in Washington, signals have real weight. They reshape how investors, partners, and complaints teams from risk. And what makes it especially important is that it's not happening in isolation. It's part of a layered framework that stretches from the NDAA to but to Biosecure Act to CFIUS and beyond. Second, the real differentiator isn't just what industry you're in, it's where you sit in the value chain. Proximity to early stage data, AI-driven discovery, and non-genomic level research is now a strategic sensitivity, and companies have to understand that they're positioning the innovation stack will increasingly determining their risk profile, not just in their commercial patch. And third, that and this may be in the power and it's the most actionable for leaders listening. You made it very clear that in the US system perception is not something you can spin. It's earned through sustained embedding. It's built through relationships with researchers, hospitals, patient groups, and industry bodies. It's reinforced by how you govern data, by who you partner with, and by whether you show up as a long-term participant in the innovation ecosystem, not just transactional service provider. In a sense, you refrained government affairs from being a defensive show into being a co-strategic function, one that built in the infrastructure of trust and the predictability that global competitiveness now depends on. I want to thank you for walking us through all of this with that level of depth and nuance. For our listeners, if you want to continue the conversation or understand how MedAsian is supporting companies through its International Government Affairs Network and the project Starlink work, Felix mentioned, we'll put links in the show notes. And for the broader community. Founders, speedy leaders, strategists in Chinese biotech. I think this takeaway is clear. If you want to build lasting success in the US, you need to think not just about market access, but about institutional participation, about narrative architecture, and about being seen as a necessary part of the system rather than an external challenger to it. That's it from this episode of Podcast with Matt Asian Felix. Thank you again. I'm Rex. Talk to you next time.